Form 4: Apellis Pharmaceuticals Executive Karen Lewis Reports Stock Sale to Cover Tax Obligations

Karen Lewis, Chief People Officer of Apellis Pharmaceuticals, sold 1,751 shares of common stock on January 22, 2025, to cover tax withholding obligations related to released Restricted Stock Units.

Summary

• Karen Lewis, Chief People Officer of Apellis Pharmaceuticals, filed a Form 4 with the SEC.
• On January 22, 2025, Lewis sold 1,751 shares of Apellis Pharmaceuticals (APLS) common stock at a price of $30.4255 per share.
• The sale was executed to cover tax withholding obligations on Restricted Stock Units released on January 21, 2025.
• Following the transaction, Lewis directly owns 70,615 shares of Apellis Pharmaceuticals common stock.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction (stock sale for tax obligations) and doesn't indicate any particularly positive or negative sentiment.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This sale appears to be a standard transaction to cover tax obligations.

Stakeholder Impact

• The sale of shares by an executive could have a minor impact on shareholder sentiment, but is unlikely to be significant given the reason for the sale.

Key Dates

Keywords

Form 4, Apellis Pharmaceuticals, Karen Lewis, Stock Sale, Tax Withholding, Restricted Stock Units, APLS, SEC Filing